Treatment of obesity with liraglutide in cardiovascular prevention: Case series by the "ITACARE-P Light-Heart Lab" working group.
作者信息
Maranta Francesco, Buffoli Francesca, Giudici Vittorio, Malfatto Gabriella, Maloberti Alessandro, Maresca Luigi, Passaretti Bruno, Torri Anna, Turato Roberto, Ambrosetti Marco
机构信息
Cardiovascular Rehabilitation Unit, San Raffaele Scientific Institute, Milan, Italy.
Cardiovascular Rehabilitation Unit, ASST Mantova, Mantova, Italy.
出版信息
Int J Cardiol Cardiovasc Risk Prev. 2024 Apr 27;21:200272. doi: 10.1016/j.ijcrp.2024.200272. eCollection 2024 Jun.
Abstract
摘要
相似文献
1
Treatment of obesity with liraglutide in cardiovascular prevention: Case series by the "ITACARE-P Light-Heart Lab" working group.利拉鲁肽用于心血管疾病预防的肥胖治疗：“ITACARE-P轻心实验室”工作组的病例系列研究
Int J Cardiol Cardiovasc Risk Prev. 2024 Apr 27;21:200272. doi: 10.1016/j.ijcrp.2024.200272. eCollection 2024 Jun.
2
Cardiopulmonary exercise testing in cardiac rehabilitation: From the reporting form to structured exercise prescription. A proposal from the Italian alliance for cardiovascular rehabilitation and prevention (Itacare-P).心脏康复中的心肺运动测试：从报告表到结构化运动处方。来自意大利心血管康复与预防联盟（Itacare-P）的一项提议。
Int J Cardiol Cardiovasc Risk Prev. 2023 Jun 16;18:200191. doi: 10.1016/j.ijcrp.2023.200191. eCollection 2023 Sep.
3
What the ITACARE-P Light-Heart and Sweet-Heart projects have taught us.ITACARE-P轻心与甜心项目给我们的启示。
Int J Cardiol Cardiovasc Risk Prev. 2024 Apr 27;21:200274. doi: 10.1016/j.ijcrp.2024.200274. eCollection 2024 Jun.
4
Position paper ITACARE-P/FADOI on the referral from internal medicine to cardiac rehabilitation: Executive summary and factsheet.ITACARE-P/FADOI关于从内科转诊至心脏康复的立场文件：执行摘要与情况说明书
Int J Cardiol Cardiovasc Risk Prev. 2024 Apr 30;21:200275. doi: 10.1016/j.ijcrp.2024.200275. eCollection 2024 Jun.
5
[Management of patients with type 2 diabetes during cardiac prevention and rehabilitation. An expert opinion from the Italian Alliance for Cardiovascular Rehabilitation and Prevention (ITACARE-P)].[2型糖尿病患者在心脏预防与康复期间的管理。来自意大利心血管康复与预防联盟（ITACARE-P）的专家意见]
G Ital Cardiol (Rome). 2023 Oct;24(10):834-843. doi: 10.1714/4100.40985.
6
41Bridging the gender gap in Cardiac Rehabilitation. The first step: The equal opportunities project.41弥合心脏康复领域的性别差距。第一步：平等机会项目。
Int J Cardiol Cardiovasc Risk Prev. 2024 Apr 27;21:200268. doi: 10.1016/j.ijcrp.2024.200268. eCollection 2024 Jun.
7
Cardiovascular Effects of Liraglutide.利拉鲁肽的心血管效应
Curr Hypertens Rev. 2019;15(1):64-69. doi: 10.2174/1573402114666180507152620.
8
Adding liraglutide to diet and exercise to maintain weight loss - is it worth it?在饮食和运动的基础上添加利拉鲁肽以维持体重减轻——是否值得？
Expert Opin Pharmacother. 2022 Mar;23(4):447-451. doi: 10.1080/14656566.2021.2019707. Epub 2021 Dec 29.
9
Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study).评估利拉鲁肽对年轻2型糖尿病患者心脏功能和结构影响的随机对照试验的原理与设计（LYDIA研究）
Cardiovasc Diabetol. 2016 Jul 21;15(1):102. doi: 10.1186/s12933-016-0421-6.
10
Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials.利拉鲁肽与超重或肥胖成年人的心血管结局：SCALE 随机对照试验的事后分析。
Diabetes Obes Metab. 2018 Mar;20(3):734-739. doi: 10.1111/dom.13125. Epub 2017 Nov 1.
本文引用的文献
1
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
2
Corrigendum to: 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC).勘误：《2021年欧洲心脏病学会临床实践中心血管疾病预防指南》：由临床实践中心血管疾病预防工作组与欧洲心脏病学会及12个医学学会代表共同制定，欧洲预防心脏病学协会（EAPC）提供特别贡献。
Eur Heart J. 2022 Nov 7;43(42):4468. doi: 10.1093/eurheartj/ehac458.
3
Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect.在2型糖尿病患者的真实世界中，利拉鲁肽通过降低小而密低密度脂蛋白来减少颈动脉内膜中层厚度：一种新的抗动脉粥样硬化作用。
Diabetes Ther. 2021 Jan;12(1):261-274. doi: 10.1007/s13300-020-00962-3. Epub 2020 Nov 18.
4
Cardiologist and Diabetologist crosstalk in the era of cardiovascular outcome trials of novel glucose-lowering drugs.新型降糖药物心血管结局试验时代心脏病专家与糖尿病专家的对话
Int J Cardiol Heart Vasc. 2018 Oct 24;21:80-86. doi: 10.1016/j.ijcha.2018.10.001. eCollection 2018 Dec.
5
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.利拉鲁肽 3.0 毫克在体重管理中的随机、对照试验。
N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892.
Zotero 插件